Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PanOptica Inc.

This article was originally published in Start Up

Executive Summary

The founders of PanOptica are inspired by the big impact VEGF-inhibitors originally developed for cancer are having on the ophthalmic market. So much so, that they company aims to search out compounds from other disease areas such as cancer, diabetes and other metabolic disorders, and find those likely to have potential for serious eye disorders.

You may also be interested in...



Start-Up Quarterly Statistics, Q1 2011

Biopharma and medical device start-ups brought in a total of $216 million in Q1 2011. Absent were any financings involving in vitro diagnostics companies. Only four acquisitions involving start-ups were completed - one in biopharma and three in the device industry. Cancer was the most popular therapeutic category among biopharma start-up alliance this quarter.

Start-Up Quarterly Statistics, Q1 2011

Biopharma and medical device start-ups brought in a total of $216 million in Q1 2011. Absent were any financings involving in vitro diagnostics companies. Only four acquisitions involving start-ups were completed - one in biopharma and three in the device industry. Cancer was the most popular therapeutic category among biopharma start-up alliance this quarter.

Researchers To Tackle New Macular Degeneration Target Using Antisense

A research team has identified a way to treat the dry form of advanced age-related macular degeneration, for which no therapy exists to halt the associated vision loss. The team expects to start clinical testing of an antisense compound to address the problem, an accumulation of a type of RNA, by the end of the year.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel